Lupin

Indian pharmaceutical major Lupin Limited has received approval from the U.S. Food and Drug Administration for its generic version of a widely prescribed anti-seizure medication, reinforcing its strategic focus on complex generics in the United States. The regulatory clearance enables the company to market the product in the world’s largest pharmaceutical market, where demand for cost-effective neurological therapies remains robust. The approval is expected to bolster Lupin’s U.S. revenues and enhance its competitive positioning.

Pharmaceutical major Lupin Ltd. is facing regulatory scrutiny after officials from the Maharashtra Goods and Services Tax Department conducted a search operation at one of its offices. The action, linked to potential discrepancies in tax filings and input tax credit claims, signals heightened enforcement across India’s corporate landscape. While the company has stated it is cooperating fully with authorities, the development underscores increasing compliance expectations for large enterprises.

Pharma major Lupin has entered a strategic licensing agreement to manufacture and commercialize injectable Semaglutide, a leading therapy for type 2 diabetes, positioning itself to capitalize on the rapidly growing global diabetes treatment market. The deal aligns with Lupin’s broader strategy to strengthen its specialty care portfolio while leveraging its manufacturing and regulatory expertise. Analysts suggest this move could drive revenue growth, diversify product offerings, and enhance the company’s presence in high-margin therapeutic areas.

Indian pharmaceutical major Lupin Ltd. has announced plans to invest USD 250 million in establishing a new manufacturing facility in the United States, marking a major step in its global expansion strategy. The move aims to strengthen Lupin’s presence in the world’s largest pharmaceutical market and enhance its production capabilities in complex generics and specialty products. The facility will cater to both domestic and export markets, reinforcing the company’s commitment to quality manufacturing, innovation, and compliance with global regulatory standards.